News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Skinvisible, Inc. (SKVI) Granted U.S. Patent for Topical Drug Delivery Technology


12/5/2012 9:55:33 AM

LAS VEGAS, NV--(Marketwire - December 04, 2012) - Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) (OTCBB: SKVI) today announced that it has been granted US Patent Number 8,318,818 for methods of manufacturing its topical drug delivery technology, Invisicare®. The patent issued by the United States Patent and Trademark Office (USPTO) entitled "Topical Composition, Topical Composition Precursor, and Methods For Manufacturing and Using," will provide protection for Invisicare until February 2029. This is one of a series of three patents granted in the United States specifically protecting Invisicare. This patent is a divisional patent stemming from Skinvisible's main US patent and follows an announcement last week of the granting of a separate US patent for retinoids made with Invisicare.

This patent further protects the composition of Invisicare; a delivery technology used to bind active ingredients to the skin. Other key benefits include controlling the release of active ingredients and decreasing skin irritation. The patent covers a vast array of skin treatments including anti-acne, antifungals, anti-inflammatory, antimicrobials or any drug delivered to the skin with Invisicare. Additionally, skincare products such as anti-aging formulations, sunscreens and moisturizers have extended protection with the granting of this patent.

"The granting of this latest patent is fundamental to our intellectual property portfolio for Invisicare. Our products become highly desirable when you can provide new benefits to products and protect them from duplication in the marketplace as Invisicare can," said Terry Howlett, President and CEO. "Our patents increase the value of Skinvisible as a company and provide our potential licensees with a strong competitive position in the dermatology, skincare and topical drug marketplace." He added, "We expect our increased patent protection will assist us greatly in our discussions with potential licensees of our products."

Skinvisible's intellectual property portfolio for Invisicare includes: U.S.(3), Canada, Europe(4), Australia, India, Japan, China, Hong Kong and S. Korea along with three product specific US patents covering its dermal barrier products, sunscreen formulations and retinoids. Skinvisible is focused on strengthening its global patent portfolio with a number of patents pending for Invisicare as well as its forty plus prescription, over-the-counter and cosmeceutical formulations it has developed.

About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing skin irritation. Skinvisible receives a combination of license fees, and ongoing royalties for its licensed product formulations. Skinvisible's value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. www.skinvisible.com and www.invisicare.com.

Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending September 30, 2012).


Corporate Contact:
Doreen McMorran
Skinvisible Pharmaceuticals, Inc.
Phone: 702-433-7154
Email: info@skinvisible.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES